Scientists at City of Hope have collared a tricky culprit that helps cancer cells evade CAR T cell therapy. CAR T cell therapy harnesses the immune system to seek out and kill tumor cells. This treatment is used in certain types of leukemia and lymphom…
Craniopharyngioma (CP) is a rare brain tumor that develops in the regions close to the hypothalamus and pituitary gland. The CP tumors lead to complications like defective vision, neuronal defects, diabetes, and developmental problems.
Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, “Combination CXCR4 an…
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation factor 15 (GDF-15) can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors.
Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective. Thus, finding …
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers…
Researchers from the Data Science and Artificial Intelligence Institute (DATAI) at the University of Navarra have developed artificial intelligence (AI) models to personalize immune therapies for oncology patients.
Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough in cancer immunotherapy research. Led by Professors Sin-Hyeog Im and Dipayan Rudra, the research team, with Dr. Amit Sharma as …
Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers…
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer an…
